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SUMMARY. Cylin dependent kinases (CDKs) have emerged as novel mechanistic target due to their direct
involvement in underlying genetic changes during the cancerous state. In order to identify the essential
physiochemical parameters for CDK2 inhibitory activity in some 3-aminopyrazole derivatives, Quantita-
tive Structure-Activity Relationship (QSAR) studies have been carried out on a series of total 35 com-
pounds (taking 24 and 11 molecules in trainings set and test set respectively) using the multiple linear re-
gression MLR) method. Among the generated models, the best QSAR model with good correlation coeffi-
cient (r2 = 0.643) along high statistical significance (> 99.9 %) well explained variance in activity for both
training and test set molecules (Pred. r2 = 0.632). The two dimensional QSAR studies revealed that the ac-
tivity is positively controlled by the indicator parameter (I), electronic parameter (field effect, F) and hy-
drophobic fragmentation constant (Fr) of substituents. Apart from that one of the interesting finding is
that this model well discriminates between the Molar refractivity (MR) and hydrophobic fragmentation
constant (Fr) in prediction of inhibitory activities based on the regression coefficient and associated error.
Further the calculation of important descriptors like log P, hydrogen bond donor and acceptors etc. indi-
cates the potential of these molecules in clinical trial as an anticancer drug. 
